Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Camille Bratton"'
Autor:
Jenna Wilson, Debra G Wheeler, Laura J. Sommerville, David Dornbos, Kendyl Carlisle, Nicholas Venetos, Richard C. Becker, Shahid M Nimjee, Juliana M. Layzer, George A. Pitoc, Nicholas Musgrave, Allyson Huttinger, Spencer Talentino, Shoeb I. Khan, Holly Moody, Bruce A. Sullenger, Jay L. Zweier, Camille Bratton, Rachel E. Rempel, Matthew Joseph, Maureane Hoffman, Cheyenne Jones
Publikováno v:
Mol Ther
Endothelial surface and circulating glycoprotein von Willebrand factor (vWF) regulates platelet adhesion and is associated with thrombotic diseases, including ischemic stroke, myocardial infarction, and peripheral vascular disease. Thrombosis, as man
Autor:
Chandan K. Sen, Shahid M Nimjee, Allyson Huttinger, Bruce A. Sullenger, Debra G Wheeler, David Dornbos rd, Spencer Talentino, Cheyenne Jones, Nicholas Venetos, Camille Bratton, Juliana M. Layzer, Matthew Joseph, Nicholas Musgrave, Surya Gnyawali
Publikováno v:
J Vis Exp
Occlusive arterial thrombosis leading to cerebral ischemic stroke and myocardial infarction contributes to ~13 million deaths every year globally. Here, we have translated a vascular injury model from a small animal into a large animal (canine), with
Autor:
Shahid M Nimjee, Jenna Wilson, Caitlin M Hatten, Debra G Wheeler, Camille Bratton, Allyson Huttinger, Gabriel S Shimmin, Cole Anderson, Spencer Talentino, Chase M Byington, Matthew Joseph
Publikováno v:
Circulation Research. 123
Objective: To compare the prophylactic and thrombolytic effects of RNA aptamer (9.14T79VRT7) on ex vivo canine platelet function. Approach and Results: We previously demonstrated that inhibition of von Willebrand Factor (VWF) by a targeted RNA aptame
Autor:
Jenna Wilson, Debra G Wheeler, Allyson Huttinger, David Dornbos, Spencer Talentino, Jay L. Zweier, Cheyenne Jones, Chandan K. Sen, Cameron Rink, Nicholas Musgrave, Hallie Harris, Nicholas Venetos, Shahid M Nimjee, Camille Bratton, Surya Gnyawali, Kendyl Carlisle
Publikováno v:
Stroke. 49
Introduction: While recombinant tissue plasminogen activator (rTPA) is the mainstay of ischemic stroke treatment, recanalization is only achieved in 25-50% of patients. With a significant risk of intracranial hemorrhage, its use has been limited to w